SYGNIS Pharma AG Announces Management Board Changes

SYGNIS Pharma AG Announces Management Board Changes


Heidelberg, March 25, 2013 - SYGNIS Pharma AG (Frankfurt: LIO1; ISIN: DE000A1RFM03, Prime Standard), today announced that Chief Financial Officer (CFO) and member of the Management Board, Peter Willinger will be stepping down effective 31 March 2013 for personal reasons. He is leaving the company by mutual agreement with the Supervisory Board. Pilar de la Huerta, the company's CEO since 2012 and a former senior manager and CFO at Zeltia, S.A., the largest Spanish quoted biotech company, will now hold both positions, CFO and CEO.

Suggested Articles

Xevinapant in combination with standard cisplatin-based chemoradiation therapy (CRT) reduces the risk of death in high-risk patients with locally adva

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.